

**UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes**

Meeting Date: December 8, 2022  
 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:00 PM		
<b>A. Minutes from previous meetings</b>	G. Shutzberg	<b>Review of Minutes from September 8, 2022</b>	Minutes reviewed, approved	<b>Yes</b>
<b>B. Formulary Review - New Drugs</b>	S. Kramzer	<b>Camzyos</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	S. Kramzer	<b>Kyzatrex</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	G. Johnson	<b>Mounjaro</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	G. Johnson	Comment: Discussion held about the origin of the brand name Mounjaro.		
	G. Johnson	<b>Ryaltris</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	S. Kramzer	<b>Voquezna</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	G. Johnson	<b>Vtama</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	G. Johnson	<b>Zoryve</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	G. Johnson	Comment: Discussed clinical trials and the lack of outcomes focused on the examination of outbreak frequencies in the patient populations.		
	S. Kramzer	<b>Ztalmly</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
<b>B. Formulary Review - PDL Modifications</b>	M. Reisman	<b>Confirm Review of PDL Modifications Grid</b> Recommendation: • <b>Ella</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
	M. Reisman	Comment: Discussion about the availability of Plan B in our state markets. Reviewed Ella's mechanism of action, dosing and difference to Plan B.		
	M. Reisman	Recommendation: • <b>Phospha 250 Neutral</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
<b>B. Formulary Review - New Drugs- Medical</b>	M. Reisman	<b>Confirm Review of New Drugs- Medical Grid</b>	Yes/No	Yes
	M. Reisman	<b>Amvuttra</b> Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	12:0
<b>B. Formulary Review - Drugs Evaluated Per Grid</b>	M. Reisman	<b>Apply recommendations as outlined in grid</b>	Motion made, seconded, and carried to accept recommendation	12:0
<b>C. Clinical Guidelines</b>	M. Reisman	<b>Clinical Guideline Review</b>		
	M. Reisman	<b>Apply New Pharmacy Guidelines</b>	Motion made, seconded, and carried to accept recommendation	12:0
	M. Reisman	<b>Continue to Apply Pharmacy Guidelines Requiring Modifications</b>	Motion made, seconded, and carried to accept recommendation	12:0
	M. Reisman	<b>Remove Pharmacy Guidelines Requiring Archival</b>	Motion made, seconded, and carried to accept recommendation	12:0
<b>D. Annual PDL Ratification</b>	G. Shutzberg	<b>Approve Preferred Drug Lists (PDLs) for each market, including the Wrap Plan File</b>	Motion made, seconded, and carried to accept recommendation	12:0
<b>E. Quality Monitoring</b>	M. Theys/M. Reisman	<b>Confirm Review of Quality Data</b>	Yes/No	Yes
	M. Theys	DUR Review		
	M. Reisman	COVID Dashboard		
	M. Reisman	Drug Recalls Q3 2022		
	M. Reisman	Comment: Discussion on infant formula and potential changes to industry standard to help mitigate the ongoing shortage.		
	M. Reisman	Top 25 Drugs by Cost and Volume – 3rd Quarter 2022		
	M. Reisman	Top 10 Drugs Requested - Approvals and Denials – 3rd Quarter 2022		
	M. Reisman	Grievances and Appeals Data – 3rd Quarter 2022		
	M. Reisman	Inter-Rater Reliability (IRR) – 3rd Quarter 2022 • Pharmacists • Medical Director (4th Quarter 2022)		
<b>Adjournment</b>	G. Shutzberg	6:30 PM		
<b>Proposed 2023 P&amp;T Dates</b>	<b>March 9th</b>	<b>June 8th</b>	<b>September 14th</b>	<b>December 14th</b>

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.  
 Chief Pharmacy Officer, UHC C&S